Xintian Pharmaceutical: First Quarter Report 2025
Xintian Pharmaceutical: 2024 Annual Report Summary
Xintian Pharmaceutical: 2024 Annual Report
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Guiyang Xintian Pharmaceutical (002873.SZ): Received 29 trademark registration certificates, 3 trademark renewal registration certificates, and 1 appearance design patent certificate.
On March 26, GELONGHUI reported that Guiyang Xintian Pharmaceutical (002873.SZ) announced that recently, Guiyang Xintian Pharmaceutical Co., Ltd. received 29 newly issued trademark registration certificates, 3 trademark renewal registration certificates, and 1 design patent certificate from the National Intellectual Property Administration.
Xintian Pharmaceutical Completes License Amendment
Market Might Still Lack Some Conviction On Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) Even After 45% Share Price Boost
